Category Archives: Treatments

Allergan obtains patent: “Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases”

December 26, 2017: Allergan, Inc. of Irvine, CA, obtained U.S. Patent No. 9,850,264, “Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases”.

According to the abstract of the patent:

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09850264.

Allergan obtains patent: “Prevention and treatment of ocular side effects with a cyclosporin”

December 12, 2017: Allergan, Inc. of Irvine, CA, obtained U.S. Patent No. 9,839,667, “Prevention and treatment of ocular side effects with a cyclosporin”.

According to the abstract of the patent:

The present disclosure relates to methods of treatment or prevention of ocular conditions caused by treatment with certain therapeutically active agents. The methods can include administering a cyclosporine, an analog or derivative thereof, or a combination thereof to an eye of a mammal suffering from an ocular condition cased by treatment with certain therapeutically active agents, which can include a chemotherapy agent or an antiviral agent.

Claim 1 of the issued patent recites:

1. A method of treating keratoconjunctivitis, the method comprising the step of administering cyclosporin A to a mammal in need thereof, wherein the mammal is suffering from keratoconjunctivitis associated with the use of a therapeutically active agent comprising capecitabine.

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09839667.

JeniVision obtains patent: “Use of prostacyclin antagonists for treating ocular surface nociception”

November 28, 2017: JeniVision, Inc. of Irvine, CA, obtained U.S. Patent No. 9,827,225, “Use of prostacyclin antagonists for treating ocular surface nociception”.

According to the abstract of the patent:

The present invention relates generally to the use of compositions and methods for treating nociceptive events that occur on the ocular surface in association with dryness, injury, environmental pollutants, and infectious and non-infectious diseases. Specifically, the present invention is directed to the use of certain compounds for treating for treating ocular pain or ocular discomfort.

Claim 1 of the issued patent recites:

1. A method of treating corneal nociception in a patient comprising administering to at least one eye of the patient a therapeutically effective amount of the following compound, or a pharmaceutically acceptable salt thereof, in a topical ophthalmic formulation having a concentration from about 0.01% (w/v) to about 10% (w/v):

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09827225.

JeniVision obtains patent: “Quantitative peri-orbital application of ophthalmology drugs”

November 21, 2017: JeniVision, Inc. of Irvine, CA, obtained U.S. Patent No. 9,820,954, “Quantitative peri-orbital application of ophthalmology drugs”.

According to the abstract of the patent:

The present invention is directed methods of lowering intraocular pressure in a patient suffering from elevated intraocular pressure or glaucoma and treating ocular disease by administering a drug to the periorbital skin of the patient.

Claim 1 of the issued patent recites:

1. A method of lowering intraocular pressure in a patient suffering from elevated intraocular pressure comprising administering a therapeutically effective amount of a composition comprising 3-[(3’-fluoro-4-fluorobiphenyl-3-carbonyl) amino] phenoxyacetic acid isopropyl ester to the periorbital skin of an eye of the patient wherein the 3-[(3’-fluoro-4-fluorobiphenyl-3-carbonyl) amino] phenoxyacetic acid isopropyl ester is applied as a topical composition having a concentration of about 0.01% to about 10% (w/w).

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09820954.

Allergan obtains patent: “Method of treating conditions with kinase inhibitors”

November 21, 2017: Allergan, Inc. of Irvine, CA, obtained U.S. Patent No. 9,820,989, “Method of treating conditions with kinase inhibitors”.

According to the abstract of the patent:

The present invention relates to a method of treating ophthalmic diseases and conditions, e.g. diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, etc., in a subject comprising administering to said subject a therapeutically effective amount of at least one compound of formula I

or a prodrug, pharmaceutically acceptable salt, racemic mixtures or enantiomers of said compound. The compounds of formula I are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

Claim 1 of the issued patent recites:

1. A method of treating an ophthalmic disease selected from the group consisting of diabetic retinopathy, age-related macular degeneration, pterygium, and retinopathy of prematurity, comprising administering to a patient in need of said treatment an effective amount of at least one compound of Formula II:

or a pharmaceutically acceptable salt thereof, wherein R2 is selected from the group consisting of

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09820989.

Allergan obtains patent: “Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues”

November 21, 2017: Allergan, Inc. of Irvine, CA, obtained U.S. Patent No. 9,820,995, “Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues”.

According to the abstract of the patent:

Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.

Claim 1 of the issued patent recites:

1. A method for treating a posterior eye disease in a patient in need thereof, the method comprising administering to the eye of the patient an ophthalmic composition comprising: a therapeutically effective amount of a Glucocorticoid Derivative (GD) comprising an acyl group linked to C17, C21, or combination thereof via an ester linkage, and a viscosity-inducing component.

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09820995.

SynergEyes: Application published: “Hybrid Contact Lens”

November 16, 2017: The USPTO today published a patent application filed by SynergEyes, Inc. of Carlsbad, CA: U.S. Application Publication No. 2017/0329155, “Hybrid Contact Lens”.

According to the published abstract:

A hybrid contact lens has a rigid gas permeable (RGP) central portion and a soft flexible portion that extends outward from the RGP central portion. The soft flexible portion defines the posterior surface and base curve of the hybrid contact lens that contacts a user’s cornea, such that the RGP central portion does not contact the user’s cornea while wearing the hybrid contact lens. The hybrid contact lens can be a single lens system with one optical power, or a dual lens system with two different optical powers.

The published application can be viewed at the USPTO website at http://pdfaiw.uspto.gov/.aiw?Docid=20170329155.

Note: A published application is not an issued patent. The USPTO automatically publishes most applications 18 months after filing, and the publication is simply a copy of the as-filed application, without examination.

Allergan: Application published: “Use of Agonists of Formyl Peptide Receptor 2 for Treating Ocular Inflammatory Diseases”

November 9, 2017: The USPTO today published a patent application filed by Allergan, Inc. of Irvine, CA: U.S. Application Publication No. 2017/0320897, “Use of Agonists of Formyl Peptide Receptor 2 for Treating Ocular Inflammatory Diseases”.

According to the published abstract:

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.

Published Claim 1 recites:

1. A method of treating an ocular inflammatory disease in a subject in need of such treatment, wherein the method comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one formyl peptide receptor 2 (FPR2) agonist to the subject;
wherein the ocular inflammatory disease is selected from the group consisting of uveitis, dry eye, keratitis, allergic eye disease, infectious keratitis, herpetic keratitis, corneal angiogenesis, lymphangiogenesis, retinitis, choroiditis, acute multifocal placoid pigment epitheliopathy, Behcet’s disease, post-surgical corneal wound healing, wet age-related macular degeneration (ARMD) and dry ARMD; and
wherein the agonist is a compound represented by Formula I, or a pharmaceutically acceptable salt thereof:

wherein: R1 is sec-butyl, C6-10 aryl, –CH2–(C6-10)aryl, –CH2-heterocycle, C4-8 cycloalkyl, C3-8 cycloalkenyl or heterocycle;
R2 is halogen or methyl;
R3 is halogen;
R4 is H, methyl or halogen;
R5 is OR6 or NH2;
and R6 is H or C2-4 alkyl;

or wherein the agonist is a compound selected from the group consisting of:

<19 other agonist compounds omitted>

and pharmaceutically acceptable salts thereof.

The published application can be viewed at the USPTO website at http://pdfaiw.uspto.gov/.aiw?Docid=20170320897.

Note: A published application is not an issued patent. The USPTO automatically publishes most applications 18 months after filing, and the publication is simply a copy of the as-filed application, without examination.

Sanford-Burnham Medical: Application published: “Methods and Compositions Related to Retinoid Receptor-Selective Pathway”

November 2, 2017: The USPTO today published a patent application filed by Sanford-Burnham Medical Research Institute of La Jolla, CA: U.S. Application Publication No. 2017/0313668, “Methods and Compositions Related to Retinoid Receptor-Selective Pathway”.

According to the published abstract:

Provided herein are methods and compositions related to a retinoid receptor-selective pathway. As described herein, this pathway can be targeted to manipulate a tumor microenviroment. For example, the methods and compositions described herein can be used to induce apoptosis in a cancer cell. Further, the compositions described herein, including Sulindac and analogs thereof, can be used to target this pathway for the treatment or prevention of cancer in human patients.

Published Claim 56 recites:

56. A method of treating cancer in a patient in need thereof, wherein the method comprises administering to the patient a composition comprising a compound of formula (I), or a sodium salt thereof, wherein the compound of formula (I) has the following structure:

wherein A is a phenyl, and wherein A is substituted by one or two substituents independently selected from the group consisting of C2-3 alkyl, n-butyl, iso-butyl, sec-butyl, –CF3, a C3-C4 cycloalkyl, and a C4-C5 cycloalkylalkyl;
wherein B is a fused phenyl, and wherein B is substituted by a fluoro;
wherein R1 is –(CR5R6)nCOOH;
wherein R2 is CH3;
wherein R5 and R6 are H; and
wherein n is 1 or 2.

The published application can be viewed at the USPTO website at http://pdfaiw.uspto.gov/.aiw?Docid=20170313668.

Note: A published application is not an issued patent. The USPTO automatically publishes most applications 18 months after filing, and the publication is simply a copy of the as-filed application, without examination.

Allergan obtains patent: “Compositions and methods for lowering intraocular pressure”

October 31, 2017: Allergan, Inc. of Irvine, CA, obtained U.S. Patent No. 9,801,891, “Compositions and methods for lowering intraocular pressure”.

According to the abstract of the patent:

Disclosed herein are compositions for lowering intraocular pressure (IOP) of an eye comprising a combination IOP-lowering agents bimatoprost, brimonidine, and timolol. Further disclosed are methods for reducing IOP in the eye of a subject.

Bimatoprost is sold by Allergan, Inc. under the name LUMIGAN®. Its chemical name is (Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[1E,3S)-3-hydroxy-5-phenyl-1-penteny- l]cyclopentyl]-5-N-ethylheptenamide, and it has a molecular weight of 415.58.

Claim 1 recites:

1. A method for lowering intraocular pressure in patients suffering from elevated intraocular pressure who do not have adequate intraocular pressure control with mono or dual combination therapy, the method comprising administering to a patient a composition consisting essentially of about 0.01% w/v bimatoprost, about 0.15% w/v brimonidine tartrate, about 0.68% w/v timolol maleate, sodium phosphate dibasic heptahydrate, citric acid monohydrate, sodium chloride, and sodium hydroxide in an aqueous carrier.

The patent may be viewed at the USPTO website at http://pdfpiw.uspto.gov/.piw?Docid=09801891.